$47.03
Value $7.8B
AlkermesvsAmgen
ALKS and AMGN stock compared: price, dividend, valuation and results, from SEC filings.
+0.11%
$465.67
Value $251B
Alkermes (ALKS) has a market value of $7.8B and Amgen (AMGN) $251B. Over the last year, with dividends, ALKS moved +49.7% and AMGN +42.3%. Dividend yield: ALKS none, AMGN 2.13%.
At a glance
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ALKS$7.8B
AMGN$251B
AMGN is 32 times ALKS
Revenue, 12 months
ALKS$1.8B
AMGN$38.9B
AMGN is 22 times ALKS
Net income, 12 months
ALKS-$351.0K
AMGN$9.4B
Operating margin
ALKS3.7%
AMGN32.4%
28.7 points apart
ROIC
ALKS1.8%
AMGN16.2%
14.4 points apart
P/E
ALKS–
AMGN26.7
Dividend yield
ALKS0.0%
AMGN2.1%
2.1 points apart
5-year return
ALKS+96.1%
AMGN+157.4%
61.3 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
The price over time
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ALKS+96.1%
AMGN+157.4%
| Period | ALKSWith dividends | AMGNWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +49.7%Price +49.7% | +42.3%Price +38.5% |
| 3 years since November 13, 2023 | +96.1%+25.2% a yearPrice +96.1% | +91.0%+24.1% a yearPrice +74.6% |
| 5 years since November 12, 2021 | +96.1%+14.4% a yearPrice +96.1% | +157.4%+20.8% a yearPrice +120.3% |
| 10 years since November 15, 2016 | -20.8%-2.3% a yearPrice -20.8% | +323.6%+15.5% a yearPrice +216.7% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
Every figure
As on each company's page. A description, not a recommendation: no one figure says which is better.
ALKSAlkermesAMGNAmgen
Valuation
ALKSAMGN| Price | $47.03 | $465.67 |
|---|---|---|
| Market value | $7.8B | $251B |
| Enterprise value (EV) | $8.6B | $292B |
| P/E | – | 26.7 |
| P/E, 5-year median | 13.3 | 23.0 |
| P/B | 4.2 | 17.5 |
| EV/EBIT | 133.6 | 23.1 |
| Free cash flow yield | 2.9% | 3.8% |
Results and growth
ALKSAMGN| Revenue, 12 months | $1.8B | $38.9B |
|---|---|---|
| Net income, 12 months | -$351.0K | $9.4B |
| Free cash flow, 12 months | $227M | $9.6B |
| Earnings per share, 12 months | -$0.02 | $17.25 |
| Revenue growth, year on year | -5.3% | 10.0% |
| Revenue growth a year, past | +7.3%over 5 years | +7.6%over 5 years |
| EPS growth a year, past | – | +2.9%over 5 years |
Margins and returns on capital
ALKSAMGN| Gross margin | 82.9% | 70.9% |
|---|---|---|
| Operating margin | 3.7% | 32.4% |
| Net margin | -0.0% | 24.1% |
| ROIC | 1.8% | 16.2% |
| ROE | -0.0% | 87.8% |
Balance sheet
ALKSAMGN| Cash | $755M | $13.2B |
|---|---|---|
| Total debt | $1.6B | $54.0B |
| Net debt / EBITDA | 8.1 | 2.3 |
| Interest cover | 0.7× | 4.8× |
Dividends and buybacks
ALKSAMGN| Dividend yield | – | 2.1% |
|---|---|---|
| Dividend per share, 12 months | – | $9.94 |
| Dividend growth a year, past | – | +8.1%over 5 years |
| Buyback yield | – | – |
| Shareholder yield | – | 2.1% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
Which is bigger, Alkermes or Amgen?
By market value, Amgen ($251B) is about 32.0 times Alkermes ($7.8B), at today's prices.
How did ALKS and AMGN stock do over the last 10 years?
Since November 15, 2016, ALKS's price moved -20.8% and AMGN's +216.7%. With dividends: ALKS -20.8% (-2.3% a year), AMGN +323.6% (+15.5% a year). Past returns do not predict future ones.
Which pays the higher dividend, ALKS or AMGN?
The dividend yield at today's price is none for Alkermes and 2.13% for Amgen. Over the last twelve months they paid – and $9.94 per share.
Which has the higher profit margins, Alkermes or Amgen?
Over the last twelve months, the net margin was -0.0% for Alkermes and 24.1% for Amgen, and the operating margin 3.7% and 32.4%. Revenue was $1.8B and $38.9B.
Which is the better investment, Alkermes or Amgen?
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
Other comparisons
With each of the two, and with the largest in its sector.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.
Descriptive data from SEC filings and market prices.